TNFRSF17 and Miyoshi myopathy: In a phase I multicenter study sponsored by Nanjing Legend Biotech Inc., the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T-BCMA cell product, in patients with MM were evaluated systematically.